Open Orphan plc (ORPH:LSE) Investor Relations Material

Overview

Open Orphan Limited is a niche CRO pharmaceutical services group that specializes in testing vaccines and antivirals through human challenge clinical trials. It is a world leader in this area and operates from Europe's only 24-bedroom quarantine clinic and specializes in virology and immunology laboratory services to aid respiratory drug, antiviral, and vaccine research and development. The company prides itself on its reliable laboratory analysis, supported by scientific expertise and robust quality processes to guarantee submission-ready data. As the demand for vaccines and antivirals increases, Open Orphan's unique services and expertise are set to grow in demand.

Frequently Asked Questions

What is Open Orphan plc's ticker?

Open Orphan plc's ticker is ORPH

What exchange is Open Orphan plc traded on?

The company's shares trade on the LSE stock exchange

Where are Open Orphan plc's headquarters?

They are based in London, England

How many employees does Open Orphan plc have?

There are 51-200 employees working at Open Orphan plc

What is Open Orphan plc's website?

It is https://www.openorphan.com/

What type of sector is Open Orphan plc?

Open Orphan plc is in the Healthcare sector

What type of industry is Open Orphan plc?

Open Orphan plc is in the Biotechnology industry

Who are Open Orphan plc's peers and competitors?

The following five companies are Open Orphan plc's industry peers:

- Kitov Pharma Ltd.

- Selecta Biosciences

- NGM Biopharmaceuticals, Inc.

- Galectin Therapeutics Inc.

- Actinogen Medical